665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors. - Marron, T.; Segar, J.; Berlin, J.D.; Boccia, R.; Spira, A.I.; Powderly, J.; Chen, C.; Wainberg, Z.A.; Schanzer, J.M.; Glenn, J.; Klumpp, K.; Csiki, I.; et al. (Annals of Oncology, 2024)